Marina Díaz‐Beyá

Author

Marina Díaz‐Beyá

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer ORCID

Also Known As

Díaz-Beyá, Marina, Esmeralda de la Banda, Isabel Granada, José González-Campos, Julio Prieto-Delgado, M Díaz-Beyá, M. Díaz-Beyá, M. Díaz‐Beyá, Marina Diaz-Beya, Marina Diaz-Beyá

158

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer Universitat de Barcelona Hospital Clínic de Barcelona Josep Carreras Leukaemia Research Institute Hospital de Sant Pau

About

Marina Díaz‐Beyá is an author at Consorci Institut D'Investigacions Biomediques August Pi I Sunyer specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	286
2	Health Sciences	2	2	43
3	Engineering	1	1	60
4	Public Health	1	1	16
5	Biostatistics	1	1	16

Marina Díaz‐Beyá

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy Marta Pratcorona, Salut Brunet, Josep Nomdedéu, Blood	2013	279
The Incidence of Veno-Occlusive Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Has Diminished and the Outcome Improved over the Last Decade Enric Carreras, Marina Díaz‐Beyá, Laura Rosiñol, Biology of Blood and Marrow Transplantation	2011	201
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies Valentín Ortiz‐Maldonado, Susana Rives, María Castellà, Molecular Therapy	2020	151
Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients Alejandra Martínez‐Trillos, Anna Gayà, Margherita Maffioli, Annals of Hematology	2010	146
The lincRNA<i>HOTAIRM1</i>, located in the<i>HOXA</i>genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature Marina Díaz‐Beyá Oncotarget	2015	130
Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance Carolina García‐Vidal, Celia Cardozo-Espinola, Pedro Puerta‐Alcalde, PLoS ONE	2018	97
MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia Marina Díaz‐Beyá, Salut Brunet, Josep Nomdedéu, Leukemia Hematological MalignancyRelevant Prognostic InformationMicrorna ExpressionMolecular CategorizationEngineering	2013	60
Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene Marina Díaz‐Beyá, Alfons Navarro, Gerardo Ferrer, Leukemia Hematological MalignancyChromatinDistinctive Microrna SignatureMedicineAcute Myeloid Leukemia	2012	56
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol Álex Bataller, Ana Garrido, Francesca Guijarro, Blood Advances	2021	54
PiwiRNA-651 as marker of treatment response and survival in classical Hodgkin lymphoma Anna Cordeiro, Alfons Navarro, Anna Gayà, Oncotarget Tumor BiologyLymphoid NeoplasiaOncologyMedicineImmunology	2016	49

Page 1